133 results on '"Telser, Harry"'
Search Results
2. Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective
3. How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts
4. End-of-life healthcare expenditure: Testing economic explanations using a discrete choice experiment
5. Experience with a colorectal cancer campaign in Swiss pharmacies
6. Corrigendum to ‘The value of a QALY towards the end of life and its determinants: Experimental evidence’ [Social Science & Medicine Volume 326 (2023) 115909]
7. The Contingency of Contingent Valuation: How Much Are People Willing to Pay against Alzheimer's Disease?
8. Conclusions
9. Cost-Benefit Analysis
10. Possible Reasons for Variation in the WTP Values
11. Results
12. Data
13. Elicitation Methods
14. Study Design : Programs against Alzheimer’s Disease
15. Introduction
16. Appendix
17. Use of the incremental cost-effectiveness ratio for decision-making policies—what is the problem? A perspective paper
18. Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2]
19. Validity and Reliability of Willingness-to-Pay Estimates: Evidence from Two Overlapping Discrete-Choice Experiments
20. Consumer Resistance Against Regulation: The Case of Health Care
21. Integration der Pflege in eine einheitliche Finanzierung - Schlussbericht
22. Study Design
23. The Contingent Valuation Method in Health Care
24. Validity of discrete-choice experiments evidence for health risk reduction
25. Die Kosten der nichtübertragbaren Krankheiten in der Schweiz : Schlussbericht
26. 8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
27. Regulierungsfolgenabschätzung zur Einführung eines Referenzpreissystems in der Schweiz
28. How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts
29. Consumer Resistance Against Regulation: The Case of Health Care
30. Quelle importance accordons-nous à la qualité du système de santé?
31. Wie viel ist uns die Qualität im Gesundheitswesen wert?
32. PD49 Social Preferences In HTA: A Pilot Analysis In CLN2 Disease
33. Aging and Future Healthcare Expenditure: A Consistent Approach
34. Job Preferences of Dairy Farmers in Eastern Switzerland: A Discrete Choice Experiment
35. Personalisierte Medizin
36. Die Kosten der nichtübertragbaren Krankheiten in der Schweiz : Schlussbericht
37. Physician drug dispensing in Switzerland: association on health care expenditures and utilization
38. Cost trajectories from the final life year reveal intensity of end-of-life care and can help to guide palliative care interventions.
39. Nutzenmessung im Gesundheitswesen: Die Methode der Discrete-Choice-Experimente
40. Human enhancement
41. Cost trajectories from the final life year reveal intensity of end-of-life care and can help to guide palliative care interventions
42. Die Kosten der nichtübertragbaren Krankheiten in der Schweiz : Schlussbericht
43. Gesundheitskosten in einer alternden Gesellschaft: ein Grund für die altersbezogene Rationierung?
44. Preferenze individuali e regolamentazione dell’assicurazione sanitaria obbligatoria: un’analisi empirica relativa alla Svizzera
45. Cost–benefit analysis for health
46. Gesundheitskosten in einer alternden Gesellschaft: ein Grund für die altersbezogene Rationierung?
47. Aging and future healthcare expenditure: a consistent approach
48. A new role for consumers' preferences in the provision of healthcare
49. The Impact of Aging on Future Healthcare Expenditure
50. Kostenvergleich zwischen zwei Kombinationstherapien gegen Hepatitis C mit pegylierten Interferonen und Ribavirin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.